Table 1. Published and ongoing prospective clinical trials from KLASS group.
| Study | Year | Principal investigator | Phase | Sample (n) | Primary endpoint | Status and publication |
| KLASS, the Korean Laparoendoscopic Gastrointestinal Surgery Study; LDG, laparoscopic distal gastrectomy; ODG, open distal gastrectomy; EGC, early gastric cancer; OS, overall survival; AGC, advanced gastric cancer; RFS, relapse-free survival; LTG, laparoscopic total gastrectomy; LPPG, laparoscopic pylorus-preserving gastrectomy; TLDG, totally laparoscopic distal gastrectomy; LADG, laparoscopic-assisted distal gastrectomy. | ||||||
| KLASS-01 | 2006 | Kim HH | III | 1,400 | LDG vs. ODG for EGC: 5-year OS | Short-term (Ann Surg 2016) (12) |
| Final long-term (JAMA Oncology 2019) (13) | ||||||
| KLASS-02 | 2010 | Han SU | III | 1,050 | LDG vs. ODG for AGC: 3-year RFS | Short-term (Ann Surg 2019) (14) |
| Final long-term (JCO 2020) (15) | ||||||
| KLASS-03 | 2012 | Cho GS | II | 138 | LTG for EGC: Morbidity & mortality | Gastric cancer 2018 (16) |
| KLASS-04 | 2014 | Lee HJ | III | 256 | LPPG vs. LDG: Dumping syndrome | Finished enrollment; To be published |
| KLASS-05 | 2014 | Park DJ | III | 184 | LPG vs. LTG: Iron deficiency anemia | Finished enrollment; To be published |
| KLASS-06 | 2017 | Hyung WJ | III | 772 | LTG vs. OTG for AGC | Recruiting |
| KLASS-07 | 2017 | Park SS | III | 442 | TLDG vs. LADG | Recruiting |
| KLASS-08 | 2018 | Park YK | II/III | 238 | LDG after neoadjuvant chemotherapy | Start |
| KLASS-09 | 2019 | Kim JH | III | 94 | Onco-metabolic surgery | Start |